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Background. The incidence of hypertension in the Western countries is continuously increasing in the elderly population and
remains the leading cause of cardiovascular and morbidity. Methods. we analysed some signiﬁcant clinical trials in order to
present the relevant ﬁndings on those hypertensive population. Results. Several studies (SYST-EUR, HYVET, CONVINCE,
VALUE, etc.) have demonstrated the beneﬁts of treatment (nitrendipine, hydrochrotiazyde, perindopril, indapamide, verapamil,
or valsartan) in aged hypertensive patients not only concerning blood pressure values but also the other important risk factors.
Conclusion. Hypertension is the most prevalent cardiovascular disorder in the Western countries, and the relevance of receiving
pharmacologicaltreatment of hypertension in aged patients is crucial; in addition, the results suggest that combinationtherapy—
nitrendipine plus enalapril—could have more beneﬁts than those observed with the use of nitrendipine alone.
1.Introduction
Hypertension remains the ﬁrst cause of cardiovascular risk
and mortality worldwide, and, in people aged 65 or older,
it has been duplicated in relation to four decades before.
Alsopopulationaged80orolderisincreasing; theprevalence
of hypertension in this group of people is above 60% and
continues to grow. It is well known that hypertension is per
se associated to other risk factors such as overweight, obesity
(46.8%), tobacco abuse, or hypercholesterolemia (45.4%)
[1]. It is estimated that during the next years, 75% of the
medical practice will be aimed at the geriatric age group.
Today, everybody wishes to reach elderly without ailments or
clinical disorders that could seriously alter his quality of life.
Hypertension is one of the main medical problems aﬀecting
the elderly. Pharmacological therapeutics is especially aimed
atstudyingthatverycommonmedicalcondition.During the
last years, and before the ﬁnal ﬁndings of the Syst-Eur were
published [2], the general medical opinion considered not
to decrease blood pressure values in order to avoid possible
ischemic events and poor oxygenation of the trigger organs
(brain, myocardium, kidney, and visual organ). This strong
belief within the medical community raised the question of
whether or not aged people should receive pharmacological
treatment similarly to other younger patients. This scientiﬁc
question was raised at the beginning of the 90s about
hypertensive people aged 60–79. Until then, many clinicians
thought that it was harmful to normalize blood pressure val-
ues of aged hypertensive people because of the hypothetical
danger ofischemic eventsin the trigger organs and, then, the
possibility to provoke serious cardiovascular complications.
2.Methods
However, the results of the Systolic Hypertension in Europe
trial (Syst-Eur), where our group has actively participated,
clearly proved the beneﬁts of hypertensive treatment versus
placebo, in contrast to the nihilistic attitude to leave the
disease to itself. The signiﬁcant results of the Syst-Eur trial
are based on the research and the ten-year followup of
4,227 patients from 23 European countries. The protocol
of this trial has been described in detail before [2]. These
ﬁndings demonstrated(1)areductionincardiacmortalityin
the group of patients treated with antihypertensive agents
(nitrendipine, enalapril, and hydrochlorothiazide); (2) a
lower incidence of stroke, angina pectoris, and myocar-
dial infarction in the group receiving active treatment;2 International Journal of Hypertension
(3) a decrease in the incidence of dementia in this group.
The potential reduction up to 50% of dementia episodes
after treatment with antihypertensive agents was based on
theuseof nitrendipine(dihydropyridine calciumantagonist)
as the ﬁrst drug with an important role in increasing the
longevity of the elderly all over the world; these ﬁndings also
showed that the nonpharmacological intervention in this
disease must not be neglected [3, 4]. The results of the Syst-
Eur trial suggest that combination therapy of nitrendipine
plus enalapril could be interesting in a better prognosis
of hypertensive patients [5]. In conclusion, the beneﬁts of
the antihypertensive treatment in patients with hypertension
aged 60 or older revealed a reduction in the cases of stroke
and cardiovascular events, which has been conﬁrmed by
other studies and meta-analysis of the last years.
3.Results
Also, it is well-known that life expectancy is rising around
the world which is related to an increased risk of developing
dementia; this is becoming a major public health problem.
The Syst-Eurstudy showed thatrandomized patientsactively
treated presented a lower incidence of dementia up to 50%
(from7.7 to3.8 cases every1000patients/yr) (21 casesversus
11 cases; P = 0.05) compared to the group treated with
placebo.
Based on the placebo group, we can extrapolate that
ﬁve-year treatment of 1,000 patients with isolated systolic
hypertension could prevent 19 cases of dementia [6]. There-
fore, the conclusive results of the Syst-Eur trial showed that
physicians (internists, cardiologists, primary care, endocri-
nologists, and others) should treat hypertension drastically
inagedpatientsandtrytoreachbloodpressurevaluessimilar
to those recommended in younger populations (≤130/
80mmHg); these values should be lower when patients have
also diabetes (≤125/75mmHg).
On the other hand, several observations suggested that
calcium antagonists could have a speciﬁc neuroprotective
eﬀect. It is well known that both in vascular and mixed
or degenerative dementias the values of the minimental
state examination (MMSE) are less decreased in patients
treated with nimodipine than in those treated with placebo.
Brain aging is accompanied by alterations of intracellular
calcium regulation, which leads to several cellular disorders,
resulting in cellular death. Disorders of calcium homeostasis
are related to the brain’s aging process and the Alzheimer’s
disease. Antihypertensive treatment and reduction in blood
pressure levels decrease the risk of developing dementia
in aged patients, which is an important ﬁnding for the
public healthcare system; calcium antagonists (nitrendipine
and nimodipine) can have a speciﬁc neuroprotective eﬀect.
Important advances have been achieved relating phys-
iopathological,pathogenetic,andtherapeuticmechanisms of
arterial hypertension. However, few studies have been made
untilnowincludingthetreatmentofhypertensioninpatients
aged 80 or older. These signiﬁcant results led the researchers
to investigate whether the beneﬁts of the Syst-Eur trial
could be extrapolated to patients aged 80 or older. However,
empiric therapy is not adequate to this important pathology.
The question was the primum movens of the HYVET study
( H yp e r t e n s i o ni nt h eV e ryE l d e r l yT r i a l ) ,w h i c hw a sd e s i gn e d
to provide a clear, deﬁnitive, and scientiﬁc answer to the
treatment of hypertension in individuals older than 80 years.
The adequate control of these patients is greatly impor-
tant for the general practitioners, internists, geriatrists, and
other specialists, since hypertension together with other
chronic conditions such as diabetes, hypercholesterolemia,
and obesity are the main pathogenetic factors of cardiovas-
cular disease, which is today the ﬁrst cause of morbidity and
mortality in the Western countries. The risks and beneﬁts of
treating hypertensive patients were studied in the HYVET
trial, in which our group participated actively. The pilot
study was carried out in 1,283 patients and was supported
by the British Heart Foundation. Three diﬀerent therapies
were designed: (1) no treatment; (2) low-dose diuretic-
based regimen (hydrochlorothiazide 12.5–25mg daily); (3)
an angiotensin-converting enzyme inhibitor (lisinopril 5mg
or enalapril 10mg), following accurate inclusion and follow-
up clinical criteria, and quality of results and procedures
carried out according to protocol. The cases studied (1,283
patients) were recruited from several European countries
(Bulgaria, Spain, Romania, UK, Poland, Finland, Lithuania,
Ireland, Greece, and Serbia) [7, 8]. This study demonstrated
that treating 1,000 patients per year, 19 cases of stroke could
beprevented(nineofthemnonfatalstroke).Thegoodresults
ofthestudy led tocontinue theinvestigation (“Main HYVET
Trial”) as international randomized double-blind trial.
Around5,000patientswereincludedinthestudy.Incon-
clusion, HYVET trial demonstrated the beneﬁts of reducing
blood pressure values in patients aged 80 or older and pro-
vided clear evidencesabout the need to treat hypertension in
this growing population; this has become very important in
the clinical practice and therapeutic guides [9, 10]. For many
years, physicians have had the mistaken idea that hyper-
tension was a result of ageing and that treatment was not
necessary and no common criteria existed about the therapy
on these cases; some proposed no treatment, others sug-
gested low-dose diuretics, and others recommended the use
of other pharmacological groups (angiotensin-converting
enzymes inhibitors,calciumchannel blocker,orangiotensin-
II receptor antagonists). It is well established that hyper-
tension is frequently associated with several cardiovascular
risk factors, such as obesity, hypercholesterolemia, diabetes,
tobacco abuse, and others. This fact led to carry out new
clinical trials including hypertensive population with other
cardiovascular events, like CONVINCE (Controlled Onset
Verapamil Investigation of Cardiovascular Endpoints) study;
this is a double-blind, randomized, multicentre, interna-
tional trial which compared two initial treatments [11].
At the beginning, physicians could choice the treatment
with hydrochlorothiazide(HCTZ)oratenolol,andthepossi-
bility to add controlled-onset extended-release verapamil, if
necessary. The protocol permitted an increase of the doses
or the number of drugs until reaching values lower than
140/90mmHg.Atotalof16,602patientswereincludedinthe
study selected from 15 countries and 661 centres. The mean
age ofthepatientswas 65.6 ± 7.4years. The main risk factorsInternational Journal of Hypertension 3
Table 1: main clinical trials on hypertensive patients.
Acronym Patients Age Drugs
ACTION 7.665 63.5∗ Nifedipine GITS
ALLHAT 40.000 ≥55 years Chortalidone, amlodipine, lisinopril,
doxazosin, pravastatin
ELITE 722 ≥65 Losartan,captopril
HOT 18.790 50–80 Felodipine, hydroclorotiazide, atenolol, ACEI
INSIGH 6.321 55–80 Nifedipine, amiloride
SYST-EUR 4.227 60–79 Nitrendipine, enalapril, hydroclorotiazide
ANBP2 6.000 65–84 Enalapril versus ββ/αβ/diuretic/antiCa++
CAPP 7.000 25–66 Captopril versus ββ/diuretics
LIFE 9.193 55–85 Losartan versus atenolol
NORDIL 10.881 50–69 Diltiazem versus ββ/diuretic
PROGRESS 6.000 64∗ Perindopril. Indapamide
CONVINCE 16.602 >55 Verapamil∗∗ versus/atenolol/hydroclorotiazide
VALUE 14.400 >50 Valsartan,amlodipine
HYVET 2.100 >80 Indapamide, perindopril
∗Median Age; ∗∗VerapamilSlow Release.
oftheparticipantswere overweight(BMI≥28.5/m2,50.4%);
dyslipemia, 31.3%; tobacco abuse 22.6%; diabetes, 19.8%,
and in a lower incidence others such as known vascular
disease, left ventricular hypertrophy, previous myocardial
infarction, transient cerebral ischaemia, and so forth. Results
showed a similar eﬃciency in the reduction of the cardiovas-
cular disease with the calcium antagonist agents than with
diuretics and beta blockersagents [12].
There have been many therapeutic advances since the
development of reserpine and phenobarbital as therapeutic
agents, more than ﬁve decades ago. However, despite the
excellent advances of the last years, hypertension continues
to be the main factor of complication and cardiac death not
only in the Western population, mostly present as cerebral
infarction and coronary heart disease. At the moment, the
number of patients with controlled hypertension is under
25% all overthe world and this couldbe due to the following
reasons: (1) a diﬃcult access to the healthcare system, (2)
t h el a c ko fs y m p t o m so fh y p e r t e n s i o n ,( 3 )t h es i d ee ﬀects
of the antihypertensive agents, (4) the presence of other
risk factors (obesity, tobacco abuse, diabetes, hypercholes-
terolemia, etc.), (5) the concomitance of other associated
noncardiovascular diseases (pneumopathy, digestive disor-
ders, and osteoarticular disorders), and (6) the diﬃculty in
adjusting dosage.
Despite the therapeutic advances, uncontrolled hyper-
tension is a growing problem in the developed countries
and populations having easy access to the healthcare system.
Unfortunately, not all the hypertensive patients receive
treatment when the values of the diastolic blood pressure are
90–95mmHg, specially, when only systolic blood pressure
values between 140–160mmHg are considered. Therefore,
the aim to reach values ≤1 3 0m m H gi ss t i l lf a ra w a y .T h i si sa
very important problem, since in hypertensive people brain
alterations secondary to vascular diseases lead to intellectual
impairment and a worse quality of life of these patients
[13, 14].
TheACTIONstudy[15]wascarriedoutin7,665patients
(mean age 63.5 years) randomly assigned to treatment with
nifedipine GITS (gastrointestinal therapeutic system) and
3,840 patients treated with placebo. The study demonstrated
that after addition of nifedipine GITS to the conventional
treatment of angina pectoris, no eﬀect was observed on
major cardiovascular event-free survival, and it reduced
the need to perform angiography and coronary interven-
tions. Table 1 s h o w ss o m eﬁ n d i n g s( n u m b e ro fp a t i e n t s ,
age, and drugs used) on clinical trials in aged hypertensive
people.
4.Conclusion
Hypertension is a very important disorder in aged people
andisassociatedwithhigherriskofcardiovascularmorbidity
and mortality. The fact of reducing blood pressure values
decreases the risk for cardiac death as well as neurological,
metabolic, and musculoskeletal system sequelae in aged
people. Therefore, the aim of the antihypertensive treatment
must be to reduce cardiovascular risks and to maintain an
adequate quality of life and good functional capacity in these
patients.
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